Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.

doi:10.1158/1078-0432.CCR-23-3241

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2024

Schreck Karisa C, Strowd Roy E, Nabors Louis B, Ellingson Benjamin M, Chang Michael, Tan Sze K, Abdullaev Zied, Turakulov Rust, Aldape Kenneth, Danda Neeraja, Desideri Serena, Fisher Joy, Iacoboni Michaella, Surakus Trisha, Rudek Michelle A, Bettegowda Chetan, Grossman Stuart A, Ye Xiaobu

Abstract excerpt

PURPOSE: Although fewer than 5% of high-grade gliomas (HGG) are BRAF-V600E mutated, these tumors are notable as BRAF-targeted therapy shows efficacy for some populations. The purpose of this study was to evaluate response to the combination of encorafenib with binimetinib in adults with recurrent BRAF-V600-mutated HGG. PATIENTS AND METHODS: In this phase 2, open-label, Adult Brain Tumor Consortium (ABTC) trial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Brain Neoplasms

Share to Carbamates

Share to Glioma

Share to Neoplasm Grading

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 38446982
DOI: 10.1158/1078-0432.CCR-23-3241
PMCID: PMC11096001

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.PMID 38446982Read ↗

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.Semantic proximity Read ↗

Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.Semantic proximity Read ↗

Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).Semantic proximity Read ↗

The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.Semantic proximity Read ↗

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.Semantic proximity Read ↗

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.Semantic proximity Read ↗

A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.Semantic proximity Read ↗

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design.Semantic proximity Read ↗

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.Semantic proximity Read ↗

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.